The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial.

IST-3 collaborative group, Sandercock P, Wardlaw JM, Lindley RI, Dennis M, Cohen G, Murray G, Innes K, Venables G, Czlonkowska A, Kobayashi A, Ricci S, Murray V, Berge E, Slot KB, Hankey GJ, Correia M, Peeters A, Matz K, Lyrer P, Gubitz G, Phillips SJ, Arauz A

Open source

DOI: 10.1016/s0140-6736(12)60768-5
Published: 2012 Jun 23
Container: Lancet (London, England)
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/s0140-6736-12-60768-5,
  title = {The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial.},
  author = {IST-3 collaborative group and Sandercock P and Wardlaw JM and Lindley RI and Dennis M and Cohen G and Murray G and Innes K and Venables G and Czlonkowska A and Kobayashi A and Ricci S and Murray V and Berge E and Slot KB and Hankey GJ and Correia M and Peeters A and Matz K and Lyrer P and Gubitz G and Phillips SJ and Arauz A},
  year = {2012},
  journal = {Lancet (London, England)},
  doi = {10.1016/s0140-6736(12)60768-5},
  url = {https://doi.org/10.1016/s0140-6736(12)60768-5}
}

RIS

TY  - JOUR
TI  - The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial.
AU  - IST-3 collaborative group
AU  - Sandercock P
AU  - Wardlaw JM
AU  - Lindley RI
AU  - Dennis M
AU  - Cohen G
AU  - Murray G
AU  - Innes K
AU  - Venables G
AU  - Czlonkowska A
AU  - Kobayashi A
AU  - Ricci S
AU  - Murray V
AU  - Berge E
AU  - Slot KB
AU  - Hankey GJ
AU  - Correia M
AU  - Peeters A
AU  - Matz K
AU  - Lyrer P
AU  - Gubitz G
AU  - Phillips SJ
AU  - Arauz A
PY  - 2012
JO  - Lancet (London, England)
DO  - 10.1016/s0140-6736(12)60768-5
UR  - https://doi.org/10.1016/s0140-6736(12)60768-5
ER  -

APA

group, I. C., P, S., JM, W., RI, L., M, D., G, C., G, M., K, I., G, V., A, C., A, K., S, R., V, M., E, B., KB, S., GJ, H., M, C., A, P., K, M., P, L., G, G., SJ, P., & A, A. (2012). The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial.. Lancet (London, England). https://doi.org/10.1016/s0140-6736(12)60768-5

Source records

pubmed · retrieved 2026-09-27T01:14:12.363Z
europe-pmc · retrieved 2026-09-27T01:14:12.376Z